

Supplemental Information

SUPPLEMENTAL TABLE 4 Use of COVID-19–Related Medications During the 21-Day Episode of Care for Patients in the Study Sample by Severity Level

Medication	Acute COVID-19 Severity Level			
	Asymptomatic	Mild	Moderate	Severe
adalimumab	1–10 (0)	1–10 (0)	1–10 (0)	—
anakinra	—	1–10 (0)	1–10 (0)	35 (2)
aspirin	31 (0)	31 (0)	51 (1)	196 (11)
azithromycin	98 (0)	113 (1)	103 (3)	103 (6)
bamlanivimab	1–10 (0)	1–10 (0)	1–10 (0)	1–10 (1)
baricitinib	—	—	—	15 (1)
casirivimab	—	—	1–10 (0)	1–10 (1)
colchicine	1–10 (0)	1–10 (0)	1–10 (0)	—
convalescent plasma	—	—	—	1–10 (1)
etesevimab	1–10 (0)	1–10 (0)	1–10 (0)	1–10 (1)
hydroxychloroquine	1–10 (0)	1–10 (0)	1–10 (0)	1–10 (1)
imdevimab	—	—	1–10 (0)	1–10 (1)
Infliximab	1–10 (0)	1–10 (0)	18 (1)	32 (2)
ivermectin	1–10 (0)	1–10 (0)	—	1–10 (1)
IVIg	1–10 (0)	18 (0)	31 (1)	173 (12)
Lopinavir-ritonavir	1–10 (0)	—	—	—
nitazoxanide	1–10 (0)	1–10 (0)	1–10 (0)	—
remdesivir	—	1–10 (0)	15 (0)	163 (9)
ruxolitinib	—	1–10 (0)	—	1–10 (1)
sotrovimab	—	—	—	1–10 (1)
Systemic corticosteroids	111 (0)	111 (1)	70 (2)	124 (7)
tocilizumab	1–10 (0)	—	—	16 (1)
tofacitinib	1–10 (0)	—	—	1–10 (1)

Small cell sizes with counts from 1 to 10 patients are shown as a range. Data provided as *n* (%) unless otherwise indicated. IVIG, intravenous immune globulin. —, indicates 0 patients in that cell.

SUPPLEMENTAL TABLE 5 COVID-19–Related Symptoms, Stable Conditions, and Unstable Conditions Among Children and Adolescents Testing Positive for SARS-CoV-2, March 2020 to December 2021

	<i>n</i> (%)
Symptoms among patients with mild illness (<i>n</i> = 22 303)	
Abdominal pain	678 (3.0)
Anorexia	62 (0.3)
Cough	6817 (30.6)
COVID-19 diagnosis up to 13 d after d of test positivity	2883 (12.9)
Fatigue	712 (3.2)
Fever and chills	8828 (39.6)
Headache	2086 (9.4)
Loss of taste or smell	217 (1.0)
Myalgia	358 (1.6)
Nasal congestion	2569 (11.5)
Nausea, vomiting, or diarrhea	1379 (6.2)
Respiratory symptoms	265 (1.2)
Sore throat	4802 (21.5)
Health conditions among patients with moderate illness (<i>n</i> = 3781)	
Bronchiolitis	286 (7.6)
Bronchitis	751 (19.9)
Gastroenteritis/dehydration	989 (26.2)
IV fluid administration in ED	2068 (54.7)
Pneumonia	349 (9.2)
Unstable conditions among patients with severe illness (<i>n</i> = 1766)	
Acute respiratory distress syndrome	695 (39.0)
COVID-19–related severe sequelae	299 (16.9)
Death	27 (1.5)
ICU admission	813 (46.0)
Mechanical ventilation	601 (34.0)
Invasive	412 (23.3)
Noninvasive	421 (23.8)
Vasopressors and inotropes	205 (11.6)
Respiratory failure	614 (34.8)
Sepsis	166 (9.4)
Shock	178 (10.1)

IV, intravenous.